Home » Stocks » IDRA

Idera Pharmaceuticals, Inc. (IDRA)

Stock Price: $1.01 USD -0.01 (-0.98%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $1.00 -0.01 (-0.99%) May 13, 6:19 PM
Market Cap 51.03M
Revenue (ttm) n/a
Net Income (ttm) -11.87M
Shares Out 41.19M
EPS (ttm) -3.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $1.01
Previous Close $1.02
Change ($) -0.01
Change (%) -0.98%
Day's Open 1.04
Day's Range 0.97 - 1.06
Day's Volume 1,232,081
52-Week Range 0.97 - 6.14

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

EXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended Marc...

2 weeks ago - GlobeNewsWire

Even the best penny stocks have their dog days. Here's a celebration of this week's weirdest plays: SNES, IDRA, SOS, TSNPD and HLLPF.

Other stocks mentioned: HLLPF, SNES, SOS
1 month ago - InvestorPlace

The company's experimental cancer drug flopped in a late-stage study.

1 month ago - The Motley Fool

Shares of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) plunged more than 62% in the extended session Thursday after the biopharmaceutical company said its lead drug candidate Tilsotolimod failed to meet th...

1 month ago - Benzinga

– Objective Response Rate Endpoint Not Met – – Objective Response Rate Endpoint Not Met –

1 month ago - GlobeNewsWire

Investors need to pay close attention to Idera Pharmaceuticals (IDRA) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

ILLUMINATE-301 Continues on Track for Data Later this Month ILLUMINATE-301 Continues on Track for Data Later this Month

2 months ago - GlobeNewsWire

EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences.

4 months ago - GlobeNewsWire

Idera Pharmaceuticals (IDRA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purc...

4 months ago - GlobeNewsWire

– COO Role is Key to Preparedness for NDA Filing and Commercial Launch – – Clayton Fletcher , Head of Business Development & Strategic Planning , to Retire –

5 months ago - GlobeNewsWire

ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances

6 months ago - GlobeNewsWire

– Protects Method-of-Use in CRC and HNSCC – – Protects Method-of-Use in CRC and HNSCC –

7 months ago - GlobeNewsWire

EXTON, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that final data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimo...

7 months ago - GlobeNewsWire

Enhanced Financial Flexibility as ILLUMINATE-301 Continues on Track Enhanced Financial Flexibility as ILLUMINATE-301 Continues on Track

9 months ago - GlobeNewsWire

EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for a ...

9 months ago - GlobeNewsWire

EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of  ILLUMINATE-...

11 months ago - GlobeNewsWire

– Overall response rate of 22% – – Disease control rate of 71% – – Median overall survival of 21 months – – Key topline data from ILLUMINATE-301 expected in Q1 2021 –

1 year ago - GlobeNewsWire

EXTON, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with an institutional investor providing for...

1 year ago - GlobeNewsWire

– Completed Enrollment in ILLUMINATE-301; Top-Line Overall Response Rate (ORR) Data Expected in Q1 2021 – – Completed Enrollment in ILLUMINATE-301; Top-Line Overall Response Rate (ORR) Data Expected in ...

1 year ago - GlobeNewsWire

Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.

1 year ago - Zacks Investment Research

Overall Response Rate (ORR) Data Anticipated Q1 2021 Overall Response Rate (ORR) Data Anticipated Q1 2021

1 year ago - GlobeNewsWire

EXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional i...

1 year ago - GlobeNewsWire

EXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019 U.S. ...

1 year ago - GlobeNewsWire

EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-lik...

1 year ago - GlobeNewsWire

EXTON, Pa., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the Baird 2019 Global Healthcare Conference on Wednesday, Sept...

1 year ago - GlobeNewsWire

Idera Pharmaceuticals, Inc. (IDRA) CEO Vincent Milano on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Idera (IDRA) delivered earnings and revenue surprises of 7.14% and 1348.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. (IDRA).

2 years ago - Zacks Investment Research

Idera (IDRA) delivered earnings and revenue surprises of 13.04% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About IDRA

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. an... [Read more...]

Industry
Biotechnology
IPO Date
Jan 24, 1996
CEO
Vincent Milano
Employees
32
Stock Exchange
NASDAQ
Ticker Symbol
IDRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for IDRA stock is "Buy." The 12-month stock price forecast is 1.00, which is a decrease of -0.99% from the latest price.

Price Target
$1.00
(-0.99% downside)
Analyst Consensus: Buy